Drug discovery targets: 5-HT6 receptor

Drugs of the Future

Volumn 30, Issue 5, 2005, Pages 479-495

  Davies, Shelley L ^a   Silvestre, Jordi S ^a   Guitart, Xavier ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; AMPEROZIDE; ARIPIPRAZOLE; BVT 5182; DONEPEZIL; HALOPERIDOL; JCF 177; LY 483518; MESORIDAZINE; MOLINDONE; QUETIAPINE; RISPERIDONE; RO 046790; RO 4368554; RO 630563; RO 657199; RO 657674; RO 660074; SB 214111; SB 258510; SB 331711; SB 357134; SB 399885; SEROTONIN 6 ANTAGONIST; SEROTONIN ANTAGONIST; SGS 518; TIOTIXENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BODY WEIGHT; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD INTAKE; HUMAN; LEARNING; LIPID ABSORPTION; MEMORY CONSOLIDATION; NONHUMAN; OBESITY; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SPATIAL MEMORY;

EID: 22244452968     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.05.907630     Document Type: Review

References (69)

1. Barnes, N.M., Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38(8): 1083-152.
2. Albensi, B.C. Biological mechanisms, cerebrovascular alterations and pharmacological targets in the pathology of dementia. Drug News Perspect 2002, 15(6): 333-7.
3. Prous Science Drug R&D Backgrounders: Alzheimer's disease (online publication). Updated May 23, 2005.
4. Albert M.S., Drachman, D.A. Alzheimer's disease: What is it, how many people have it, and why do we need to know? Neurology 2000, 55(2): 166-8.
5. Prous Science Drug R&D Backgrounders: Schizophrenia (online publication). Updated May 23, 2005.
6. Sawa, A., Snyder, S.H. Schizophrenia: Diverse approaches to a complex disease. Science 2002, 296(5568): 692-5.
7. Freedman, R. Schizophrenia. New Engl J Med 2003, 349(18): 1738-49.
8. Buchanan, R.W., Summerfelt, A., Tek, C., Gold, J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003, 59(1): 29-33.
9. Davis, K.L., Thal, L.J., Gamzu, E.R., Davis, C.S., Woolson, R.F., Gracon, S.I., Drachman, D.A., Schneider, L.S., Whitehouse, P.J., Hoover, T.M. et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. New Engl J Med 1992, 327(18): 1253-9.
10. Roth, B.L., Hanizavarch, S.M., Blum, A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berlin) 2004, 174(1): 17-24.
11. Meneses, A. 5-HT system and cognition. Neurosci Biobehav Rev 1999, 23(8): 1111-25.
12. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 1996, 23(3): 164-73.
13. 6 receptor-like material in the rat central nervous system. Brain Res 1997, 746(1-2): 207-19.
14. 6 serotonin receptors. J Med Chem 2000, 43(5): 1011-8.
15. 6 receptor. Synapse 2003, 47(3): 218-24.
16. 6 receptors in nigro-striatal function in rodents. Br J Pharmacol 1998, 125(7): 1562-6.
17. 7 serotonin receptors. Pol J Pharmacol 2002, 54(4): 327-41.
18. Hirst, W.D., Abrahamsen, B., Blaney, F.E., Calver, A.R., Aloj, L., Price, G.W., Medhurst, A.D. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003, 64: 1295-308.
19. Field, A.E., Coakley, E.H., Must, A., Spadano, J.L., Laird, N., Dietz, W.H., Rimm, E., Colditz, G.A. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001, 161(13): 1581-6.
20. Khaodhiar, L., McCowen, K.C., Blackburn, G.L. Obesity and its comorbid conditions. Clin Cornerstone 1999, 2(3): 17-31.
21. Prous Science Drug R&D Backgrounders: Obesity (online publication). Updated May 20, 2005.
22. Chiesi, M., Huppertz, C., Hofbauer, K.G. Pharmacotherapy of obesity: Targets and perspectives. Trends Pharmacol Sci 2001, 22(5): 247-54.
23. Campfield, L.A., Smith, F.J., Burn, P. Strategies and potential molecular targets for obesity treatment. Science 1998, 280(5368): 1383-7.
24. Sorbera, L.A. New drug development prospects for obesity. Environner 2004, 1(1): 34.
25. 6 antisense oligonucleotide i.c.v. affects rat performance in the water maze and feeding behavior. J Psychopharmacol 1997, 11: A64.
26. 6 receptor antagonism: A novel mechanism for the management of diabetes. SMi Conf Obesity and Related Disorders (Feb 17-18, London) 2003.
27. Sleight, A.J., Boess, F.G., Bos, M., Levet-Trafit, B., Riemer, C., Bourson, A. Characterization of Ro 04-6790 and Ro 63-0563: Potent and selective antagonists at human and rat 5-HT6 receptors. Br J Pharmacol 1998, 124(3): 556-62.
28. Ro-65-7674: Drug Data Rep 1999, 21(10): 871.
29. 6 antagonists: A novel approach for the symptomatic treatment of Alzheimer's disease. 37th IUPAC Cong (Aug 14-19, Berlin) 1999, Abst MM-7.
30. 6 receptor antagonist. J Med Chem 1999, 42(2): 202-5.
31. 6 receptor antagonist. Br J Pharmacol 2000, 130(7): 1606-12.
32. 6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther 2003, 307(2): 682-91.
33. 6 receptor antagonists. 28th Natl Med Chem Symp (June 8-12, San Diego) 2002, Abst.
34. 6 receptor antagonist. Pharmacol Biochem Behav 2002, 71(4): 645-54.
35. 6 receptor antagonist. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 576.7.
36. 6 antagonist for the treatment of cognitive deficit. 229th ACS Natl Meet (March 13-17, San Diego) 2005, Abst MEDI 282.
37. 6 serotonin receptor. J Neurochem 1996, 66(1): 47-56.
38. 2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol 2003, 472(1-2): 33-8.
39. Kennedy, J.S., Southall, S.S., Rodriguez, D., Nomikos, G.G. Effects of antipsychotic drugs on acetylcholine efflux in the hippocampus of the rat. Int Psychogeriatr 2001, 13(Suppl. 2): Abst P-174.
40. 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol 2000, 130(1): 23-6.
41. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25(5): 662-8.
42. 6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 2004, 51(2): 158-64.
43. 6 antagonists: Identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1- ylbenzenesulfonamide (SB-357134). Bioorg Med Chem Lett 2001, 11(1): 55-8.
44. 6 receptor antagonist, Ro 04-6790, in rats. Br J Pharmacol 1999, 126(7): 1537-42.
45. 6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berlin) 2003, 170(4): 358-67.
46. 6 receptor antagonist RO4368554 in rats. 32nd Annu Meet Soc Neurosci (Nov 2-7 Orlando) 2002, Abst 290.2.
47. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berlin) 2001, 158(2): 114-9.
48. 6 receptor antagonist SB 271046 in behavioral models of cognition. 34th Annu Meet Soc Neurosci (Oct 23-27, San Diego) 2004, Abst 776.19.
49. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - An effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004, 47(2): 195-204.
50. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 2004, 29(1): 93-100.
51. Saegis Pharmaceuticals completes phase I clinical study of SGS518. Saegis Press Release 2005, March 29.
52. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41(2): 210-9.
53. 6 antagonist, Ro 04-6790 on food consumption in rats trained to a fixed feeding regime. Br J Pharmacol 1999, 126: 66P.
54. 6 receptor antagonist BVT.5182 reduces body weight of high fat diet-induced mice. Int J Obes 2003, 27(Suppl. 1): Abst T1:P1-094.
55. 6 receptor antagonist BVT5182 decreases food intake and body weight in both rats and mice. 34th Annu Meet Soc Neurosci (Oct 23-27, San Diego) 2004, Abst 75.8.
56. 7) positively linked to adenylate cyclase. J Biol Chem 1993, 268(31): 23422-6.
57. 6 antagonists. Bioorg Med Chem Lett 2000, 10(20): 2295-9.
58. 6 receptor antagonists: Lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur J Med Chem 2001, 36(2): 165-78.
59. 6 receptor antagonist. J Med Chem 2003, 46(7): 1273-6.
60. 6 serotonin receptor ligands. Bioorg Med Chem Lett 2004, 14(8): 1961-4.
61. 6 receptor. Bioorg Med Chem Lett 2001, 11(20): 2843-6.
62. 6 receptor ligands. J Med Chem 2001, 44(23): 3881-95.
63. 6 receptor antagonist. Br J Pharmacol 1999, 127(Suppl.): Abst 21P.
64. 6 receptor. 32nd Annu Meet Soc Neurosci (Nov 2-Nov 7, Orlando) 2002, Abst 586.9.
65. 6 receptor ligands. J Med Chem 2005, 48(6): 1781.
66. Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H.Y., Roth, B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28(3): 519-26.
67. Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R., Roth, B.L., Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28(8): 1400-11.
68. Subramanian, N., Kalkman, H.O. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuro-Psychopharmacol Biol Psychiatr 2002, 26(3): 553.
69. Kalkman, H.O., Subramanian, N., Hoyer, D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001, 25(6): 904-14.